Mini Review
Volume 6 Issue 2 - November 2017
DOI: 10.19080/ADOH.2017.06.555682

What Should Oral Health Clinicians Tell their Patients about Oral HPV?

Juliet Dang*
University of Washington, USA

Submission: March 14, 2017; Published: November 15, 2017
*Corresponding author: Juliet Dang, PhD, MS, University of Washington, 4414 MLK JR Way S, Seattle, WA 98108, USA, Tel: 206.359.0134; Email: jhtdang@gmail.com

Introduction

In the United States, it is estimated that there are at least 20 million new cases of sexually transmitted infections (STIs) each year, with a prevalence of 110 million people infected, and costing the country 16 billion dollars. The Centers for Disease Control and Prevention (CDC) estimates just over 14 million new cases of HPV infection each year in the US, where half consist of young people between the ages of 15-24 [1]. Approximately 90% of HPV infections will clear within a few years without any symptoms. However, for the infections that do persist, serious health risks may be the outcome.

HPV natural history

We actually are still in the infancy stages regarding the natural history of HPV. However, the information we do have on cervical cancer guides the model for oral cavity cancer (OCC) and oropharyngeal cancer (OPC). HPVs are categorized into low-risk (wart-causing) and high-risk (cancer-causing) types. Globally, HPVs type 16 and 18 cause approximately 70% of cervical cancers [2]. The other two most common HPV types are 6 and 11, which predominantly cause genital warts. The tissues within the oropharynx are comparable to the tissues of the cervix, thus it is not surprising that we see a similar paradigm occurring between the two regions regarding HPV infection. For example, HPV can be found in precancerous lesions of the oral cavity, which is the same case in cervical cancer [3].

HPV risk factors

Internationally, over time, there have been changes in sexual behaviors with the age of sexual interaction beginning much younger; along with the increasing number of sexual partners one has [4-6]. As well, sexual practices have changed with oral sex being performed more by men and women within the 30-49 year age range compared with older adults [5]. As such, it is not surprising that we see a similar paradigm occurring between the two regions regarding HPV infection. For example, HPV can be found in precancerous lesions of the oral cavity, which is the same case in cervical cancer [3].

HPV prevention

Abstinence of any sexual behavior, including kissing, would be the most obvious form of prevention, but that is not likely to occur. Currently, there are three different types of HPV vaccines on the market. Gardasil has two kinds available: the quadrivalent vaccine, which protects against types 6, 11, 16, and 18; and the nonavalent vaccine, which protects against the same types as the quadrivalent vaccine plus five more types (31, 33, 45, 52, and 58). Cervarix has a bivalent vaccine for HPV types 16 and 18.

These results may collectively suggest a common mode of HPV transmission between the oral and genital area, reinforcing the possibility of sexual transmission of the virus in the oral cavity.

Potential reservoirs for the virus are proposed to be the tonsillar crypts [10,11] as well as periodontal pockets [12]. Also, an association between long-standing periodontitis and the risk of tongue cancers has been demonstrated [13]. A recent pilot study observed the oral health status of 223 patients and HPV infection [14]. Their results demonstrated a trend between oral HPV 16 infection and poor clinical oral health status. Thus, it is imperative that oral health practitioners continue to educate their patients on the connections between oral health status and acquiring other diseases.

HPV prevention

Abstinence of any sexual behavior, including kissing, would be the most obvious form of prevention, but that is not likely to occur. Currently, there are three different types of HPV vaccines on the market. Gardasil has two kinds available: the quadrivalent vaccine, which protects against types 6, 11, 16, and 18; and the nonavalent vaccine, which protects against the same types as the quadrivalent vaccine plus five more types (31, 33, 45, 52, and 58). Cervarix has a bivalent vaccine for HPV types 16 and 18.

The quadrivalent vaccine was introduced in 2006 and approved for males in 2009. When we look at data extracted between 2003-2006 and 2009-2012 we see evidence of vaccine efficacy in HPV prevention within women (Figure 1) [15]. For all age groups except for females 25-29, there was a decrease in the prevalence of HPV between the two time periods. Herrero et al. provided evidence that HPV vaccines used to prevent cervical cancer can be effective in preventing infection of oral HPVs.
In a randomized clinical trial in Costa Rica, 7,466 women between the ages of 18-25 years were given the bivalent vaccine for hepatitis A as a control [16]. During the last visit of the blinded 4-year study, 5,840 subjects gave oral specimens in order to evaluate vaccine efficacy (VE) against oral infections. The results demonstrated a VE of 93.3%. The authors theorized that if protection was seen in females the same should occur in males, and that this could be a primary preventative measure for HPV-related oral cancers.

**HPV detection**

Regarding oral HPV detection, there currently are only two companies that provide oral HPV testing. Oral DNA Labs provides their service to only patients that visit their oral health practitioner. SelfCollect.com also provides oral HPV testing that is available to the public without having to visit the dental office. Keiko DNA Labs is a start-up that hopes to provide a more accurate diagnostic test using Real-Time PCR.

All sampling methods from each company are non-invasive.

**HPV-associated OCC/OPC**

According to the Oral Cancer Foundation, there will be approximately 48,000 new cases of OCC/OPC annually, with a rate increase of >50% mortality rate each year globally [17,18]. Even with some improvements in scientific efforts and screening, the mortality rate of OCC remains high and the 5-year disease-free survival rate remains quite poor [19].

While HPV-associated OCCs are present, it is the HPV-associated OPCs that are more of a concern as studies have demonstrated HPV association from 30 to >90% in OPC cases. Variation between studies results from a variety of factors such as sampling technique (i.e. swab, brush, and oral rinse), method of detection (i.e. PCR, real-time PCR), and differences in type of molecules being detected (i.e. DNA, RNA, p16). The difficult aspect of HPV-associated cancer diagnosing is that transformation of HPV-infected cells to malignant lesion can take many years with little to no symptoms. Treatment of HPV-associated cancers usually consists of excision of tissues infected with malignancy along with chemotherapy or radiation therapy depending on the case.

**Closing Remarks**

Oral health practitioners have a plethora of items to discuss with their patients regarding basic oral hygiene care. However, HPV is definitely becoming a topic of conversation while visiting the dental office. Thus, when it comes to educating about oral HPV, take away items from this review are:

a. HPV is the #1 STI in the US
b. 90% of HPV infections clear within a few years
c. HPV vaccination is highly recommended for all pre-teens, and may be effective for HPV prevention in adults as well
d. Alcohol consumption, tobacco and marijuana usage, poor oral health, and sexual behaviors can increase risk of HPV infection
e. Oral HPV testing is available.

**References**


